Silo Pharma, INC Schedule 13G passive stakes

Intracoastal Capital LLC, along with individuals Mitchell P. Kopin and Daniel B. Asher, has disclosed a beneficial ownership of 125,261 shares, representing 9.99% of Silo Pharma, Inc.'s common stock.

AdvisorShares Trust has reported beneficial ownership of 75,582 shares, representing 6.69% of Silo Pharma, Inc.'s common stock, as of June 30, 2026.

Anson Funds Management LP and affiliated entities have disclosed a 4.9% beneficial ownership stake in Silo Pharma, Inc., primarily through common stock and exercisable warrants.

Intracoastal Capital LLC and its principals, Mitchell P. Kopin and Daniel B. Asher, reported a 9.99% beneficial ownership stake in Silo Pharma, Inc. as of December 31, 2025.

SEG Opportunity Fund, LLC has reported a 0.0% beneficial ownership in Silo Pharma, Inc., indicating a full divestment of its previously held stake.

Anson Funds Management LP and affiliated entities have reported a 7.2% beneficial ownership stake in Silo Pharma, Inc., totaling 952,381 shares of common stock.

Intracoastal Capital LLC, along with Mitchell P. Kopin and Daniel B. Asher, reported a continued beneficial ownership of 9.99% in Silo Pharma, Inc. common stock as of September 30, 2025.

SEG Opportunity Fund, LLC has reported a 7.1% beneficial ownership stake in Silo Pharma, Inc., totaling 952,381 shares of common stock.

Intracoastal Capital LLC, along with Mitchell P. Kopin and Daniel B. Asher, disclosed a 9.99% beneficial ownership stake in Silo Pharma, Inc., primarily through warrant holdings.

Intracoastal Capital LLC, along with Mitchell P. Kopin and Daniel B. Asher, has disclosed a 9.99% beneficial ownership stake in Silo Pharma, Inc. through a Schedule 13G filing, stemming from a recent Securities Purchase Agreement.

Renaissance Technologies LLC and Renaissance Technologies Holdings Corporation have filed an amended Schedule 13G, disclosing a passive beneficial ownership of 0.84% in Silo Pharma, Inc.'s common stock as of December 31, 2024.